The expression and significance of interleukin-35 receptor in oral lichen planus

doi:10.7518/hxkq.2020.05.007

Abstract

Abstract:

Objective To investigate the expression of glycoprotein 130 (gp130) and interleukin 12 receptor β2 (IL-12Rβ2) in two subunits of interleukin-35 receptor (IL-35R), singal transducer and activator of transcription (STAT) 1 and STAT4 in oral lichen planus (OLP) tissues, and to explore the role and significance of IL-35R in the formation and development of OLP lesions. Methods Totally 41 samples of OLP tissues (OLP group) and 15 samples of normal oral mucosa (control group) were collected. The expression levels of gp130, IL-12Rβ2, STAT1, STAT4 mRNA in the tissues were detected by real-time fluorescent quantitative polymerase chain reaction and the distribution and expression of protein gp130 and IL-12Rβ2 were detected by immunohistochemistry. The potential relationship between gp130 and IL-12Rβ2 and clinical features of OLP was analyzed. Results 1) The expression levels of gp130, IL-12Rβ2, STAT1 and STAT4 mRNA in the OLP group were significantly higher than those in the control group (P<0.05). 2) The positive expression rates of gp130 and IL-12Rβ2 protein in the OLP group were higher than those in the control group (P<0.05). The expression of gp130 and IL-12Rβ2 proteins in OLP tissues were positively correlated (r=0.984, P<0.001). 3) The expression rates of gp130 and IL-12Rβ2 protein in erosive OLP tissues were significantly higher than those in non-erosive ones (P<0.05). Conclusion The expression of IL-35R and STAT is up-regulated in OLP tissues, and the expression of IL-35R is related to the clinical classification of OLP, suggesting that IL-35R might play an important role in the formation and development of damage OLP lesions.

Key words: oral lichen planus, interleukin-35, interleukin-35 receptor, glycoprotein 130, interleukin-12 receptor β2, singal transducer and activator of transcription 1, singal transducer and activator of transcription 4

CLC Number:

R781.5

Zhang Lingyan, Wang Rong, Liu Ting, Cai Yang. The expression and significance of interleukin-35 receptor in oral lichen planus[J]. West China Journal of Stomatology, 2020, 38(5): 513-518.

Figures/Tables 5

Tab 1

Tab 2

Fig 1

Fig 2

Tab 3

References 20

[1]	陈谦明 . 口腔黏膜病学[M]. 4版. 北京: 人民卫生出版社, 2012: 103-105.
	Chen QM. Oral mucosal disease[M]. 4th ed. Beijing: People’s Medical Publishing House, 2012: 103-105.
[2]	Alrashdan MS, Cirillo N , McCullough M. Oral lichen planus: a literature review and update[J]. Arch Dermatol Res, 2016,308(8):539-551. doi: 10.1007/s00403-016-1667-2 URL pmid: 27349424
[3]	Tarasenko SV, Shatokhin AI, Umbetova KT , et al. T-cells immunity in oral lichen planus pathogenesis[J]. Stomatologiia (Mosk), 2014,93(1):60-63.
[4]	Collison LW, Workman CJ, Kuo TT , et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007,450(7169):566-569. doi: 10.1038/nature06306 URL pmid: 18033300
[5]	Niedbala W, Wei XQ, Cai BL , et al. IL-35 is a novel cytokinewith therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells[J]. Eur J Immunol, 2007,37(11):3021-3029. doi: 10.1002/eji.200737810 URL pmid: 17874423
[6]	Sawant DV, Hamilton K, Vignali DA . Interleukin-35: expanding its job profile[J]. J Interferon Cytokine Res, 2015,35(7):499-512. doi: 10.1089/jir.2015.0015 URL pmid: 25919641
[7]	Collison LW, Delgoffe GM, Guy CS , et al. The composition and signaling of the IL-35 receptor are unconventional[J]. Nat Immunol, 2012,13(3):290-299. doi: 10.1038/ni.2227 URL
[8]	Vignali DA, Kuchroo VK . IL-12 family cytokines: immunological playmakers[J]. Nat Immunol, 2012,13(8):722-728. doi: 10.1038/ni.2366 URL
[9]	Floss DM, Schönberg M, Franke M , et al. IL-6/IL-12 cytokine receptor shuffling of Extra-and intracellular domains reveals canonical STAT activation via synthetic IL-35 and IL-39 signaling[J]. Sci Rep, 2017,7(1):15172. doi: 10.1038/s41598-017-15173-3 URL pmid: 29123149
[10]	Behzadi P, Behzadi E, Ranjbar R . IL-12 family cytokines: general characteristics, pathogenic microorganisms, receptors, and signalling pathways[J]. Acta Microbiol Immunol Hung, 2016,63(1):1-25. doi: 10.1556/030.63.2016.1.1 URL pmid: 27020866
[11]	王荣, 刘芳, 江南 , 等. 口腔扁平苔藓病损组织中白细胞介素35的表达及意义[J]. 中华口腔医学杂志, 2018,53(1):13-19.
	Wang R, Liu F, Jiang N , et al. Expression and significance of interleukin-35 in lesion tissue of oral lichen planus patients[J]. Chin J Stomatol, 2018,53(1):13-19.
[12]	Schmittgen TD, Livak KJ . Analyzing real-time PCR data by the comparative C(T) method[J]. Nat Protoc, 2008,3(6):1101-1108. doi: 10.1038/nprot.2008.73 URL pmid: 18546601
[13]	Fu HY, Li C, Yang W , et al. FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape[J]. Acta Histochem, 2013,115(2):151-157. doi: 10.1016/j.acthis.2012.06.002 URL pmid: 22749378
[14]	贾沛茹, 刘芳, 柳汀 , 等. 口腔扁平苔藓病损中Th17/Treg平衡及意义[J]. 实用口腔医学杂志, 2018,34(5):39-43.
	Jia PR, Liu F, Liu T , et al. Th17/Treg balance in local lesions of oral lichen planus[J]. J Pract Stomatol, 2018,34(5):39-43.
[15]	刘芳, 蔡扬 . 白细胞介素-35及其与口腔疾病的关系[J]. 国际口腔医学杂志, 2018,45(6):716-722.
	Liu F, Cai Y . Interleukin-35 and its relationship with oral diseases[J]. Int J Stomatol, 2018,45(6):716-722.
[16]	Collison LW, Chaturvedi V, Henderson AL , et al. IL-35-mediated induction of a potent regulatory T cell population[J]. Nat Immunol, 2010,11(12):1093-1101. doi: 10.1038/ni.1952 URL pmid: 20953201
[17]	Zhang JF, Zhang YS, Wang QP , et al. Interleukin-35 in immune-related diseases: protection or destruction[J]. Immunology, 2019,157(1):13-20. doi: 10.1111/imm.13044 URL pmid: 30681737
[18]	Hao SN, Chen X, Wang F , et al. Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells[J]. Carcinogenesis, 2018,39(12):1488-1496. doi: 10.1093/carcin/bgy136 URL pmid: 30321288
[19]	Guo YF, Cao W, Zhu Y . Immunoregulatory functions of the IL-12 family of cytokines in antiviral systems[J]. Viruses, 2019,11(9):E772. doi: 10.3390/v11090772 URL pmid: 31443406
[20]	Stark GR, Darnell JE Jr . The JAK-STAT pathway at twenty[J]. Immunity, 2012,36(4):503-514. doi: 10.1016/j.immuni.2012.03.013 URL

引物	引物序列	产物大
名称	引物序列	小/bp
gp130	上游：5’-TTGAGTTGCATTGTGAACGA-3’	111
	下游：5’-CTTGTGTGTTGCCCATTCAG-3’
IL-12Rβ2	上游：5’-AAAGTTCCCTGATGGCTGTC-3’	110
	下游：5’-GAGGTGAGGTGCGTTTATGC-3’
STAT1	上游：5’-TTCCCTTCTGGCTTTGGATT-3’	133
	下游：5’-GGCTGCTGGTCCTTCAACA-3’
STAT4	上游：5’-TCCAAGTGTGTATGCGGTGT-3’	107
	下游：5’-TGGTGCGTCAGAGTTTATCCT-3’
β-actin	上游：5’-TAGTTGCGTTACACCCTTTCTTG-3’	151
	下游：5’- TCACCTTCACCGTTCCAGTTT-3’

项目	OLP组/（×10^-3）	对照组/（×10^-3）	Z值	P值
gp130	11.55（3.43,36.40）	1.25（0.85,2.80）	-3.895	<0.001^Δ
IL-12Rβ2	17.13（4.36,60.35）	4.66（1.38,14.57）	-2.600	0.009^Δ
STAT1	16.89（7.14,47.78）	2.38（1.60,3.99）	-3.876	<0.001^Δ
STAT4	6.17（2.00,26.64）	2.32（1.36,3.43）	-2.655	0.008^Δ

项目		n	gp130			IL-12Rβ2
项目		n	阳性数/%	χ²值	P值	阳性数/%	χ²值	P值
临床类型	非糜烂型	21	4/19	5.707	0.017^Δ	4/19	4.264	0.037^Δ
	糜烂型	20	11/55			10/50
病程	≥6个月	15	6/40	0.119	0.730	6/40	0.363	0.548
	<6个月	26	9/35			8/31